Close

BioNTech And Regulator Differ On COVID Jab Approval- WAS

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

According to a story in the Welt Am Sonntag (WAS) newspaper, the launch of the vaccine developed by German pharmaceutical company BioNTech for the Omicron coronavirus type may be postponed because of a dispute with the regulator over the licencing procedure. 

Ugur Sahin, the chief executive of BioNTech, does not intend to submit any more clinical trials, WAS said, citing the Financial Times. However, the regulator should still determine by the end of June whether or not to authorise the new vaccine.

According to Sahin, who was quoted by WAS, the rationale for this was that the new COVID-19 vaccine could be given in three months if the approval “should go through the same regulatory process as other flu vaccinations.”

Klaus Cichutek, the director of the Paul Ehrlich Institute (PEI), the German medical watchdog, told the newspaper that there was no justification to take a chance by skipping the regular regulatory procedure while making arrangements for the upcoming pandemic wave.

The PEI chief informed WAS that “Mr. Sahin insists that only animal evidence be given for approval of alternative vaccinations,” adding that while this may be done in an emergency, there was none at the time.

Vaccine manufacturers may be granted first licences for improved COVID-19 vaccinations in September, as per PEI and the European Medicines Agency (EMA), if the vaccine manufacturers demonstrate in human trials that they are superior to current vaccines.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back